SCHEMBL8102334

SCHEMBL8102334

CCCNC(=O)CCn1ccc(=O)c(OCc2ccccc2)c1C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ NPC1 O15118 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.54
▸ PSMB1 P20618 1/20 0.45
▸ POLB P06746 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ MAOB P27338 2/20 0.42
▸ APP P05067 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21082340 0.87 HTT (0.61) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL29243860 0.85 HTT (0.65) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL8106191 0.84 HTT (0.70) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL20382948 0.83 HTT (0.68) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3358984 0.83 HTT (0.75) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL21082280 0.82 MEN1 (0.64) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL8133893 0.81 KMT2A (0.47) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL20382958 0.81 HTT (0.71) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL9515266 0.80 HTT (0.67) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL8122829 0.79 HTT (0.73) HTTSMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36831-E TREATMENT OF IRON DEFICIENCY ANEMIA BRITISH TECHNOLOGY GROUP LTD. (GB) 2000-08-22 — — US disclosed
US-RE35948-E TREATING TOXIC METAL CONCENTRATION BY ADMINISTERING N-SUBSTITUTED 3-HYDROXYPYRID-2-ONE OR 3-HYDROXYPYRID-4-ONE BRITISH TECHNOLOGY GROUP LTD. (GB) 1998-11-03 — — US disclosed
EP-0305646-B1 3-Hydroxypyrid-4-ones and pharmaceutical compositions BRITISH TECH GROUP (GB) 1996-11-13 — — EP disclosed
EP-0305646-A2 3-Hydroxypyrid-4-ones and pharmaceutical compositions BTG INTERNATIONAL LIMITED (GB) 1989-03-08 — — EP disclosed
EP-0120670-B1 IRON III COMPLEXES OF HYDROXYPYRIDONES, AND THEIR PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-12-21 — — EP disclosed
US-4650793-A NITROGEN-SUBSTITUTED NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-03-17 — — US disclosed
US-4585780-A CHELATION OF HEAVY METALS IN BLOOD NATIONAL RESEARCH DEVELOPMENT CORP. (GB) 1986-04-29 — — US disclosed
EP-0120669-A2 Hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 — — EP disclosed
EP-0120670-A1 Iron III complexes of hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 — — EP disclosed
Send feedback